论文部分内容阅读
随着对乳腺癌生物学特性的深入研究和综合治疗方法的不断进步,乳腺癌是全身疾病的观点已达成共识,普查早诊、化放疗、内分泌及基因靶向治疗等各种方法相继问世并不断更新,以及分子水平诊治手段的发展,使乳腺癌的临床治疗进入了一个全新的时代。应该说,临床研究为乳腺癌患者打开了一扇幸运门。对此,如果患者有机会参加一些国际多中心临床研究,尝试新的靶向药物联合的治疗方案,利益与风险并存,也是一种较好的选择,既给患者治疗带来一次新的机会,也为临床研究带来更多的信息,为更多患者的选择提供了参考。
With the in-depth study of the biological characteristics of breast cancer and the continuous advancement of comprehensive treatment methods, a consensus has been reached on the view that breast cancer is a systemic disease. Various methods such as census, early diagnosis, radiotherapy, endocrinology, and gene-targeted therapy have been developed. Constantly updated, and the development of molecular methods of diagnosis and treatment, so that the clinical treatment of breast cancer has entered a new era. It should be said that clinical research has opened a lucky gate for breast cancer patients. In this regard, if patients have the opportunity to participate in a number of international multi-center clinical research, try a new targeted drug combination of treatment programs, benefits and risks coexist, is also a good choice, not only brings a new opportunity for patient treatment, It also brings more information for clinical research and provides a reference for the selection of more patients.